The impact of illicit drug use and substance abuse treatment on adherence to HAART

被引:64
作者
Hicks, P. L. [1 ]
Mulvey, K. P. [2 ]
Chander, G. [1 ]
Fleishman, J. A. [3 ]
Josephs, J. S. [1 ]
Korthuis, P. T. [4 ]
Hellinger, J. [5 ]
Gaist, P. [6 ]
Gebo, K. A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA
[2] Substance Abuse & Mental Hlth Serv Adm, Ctr Substances Abuse Prevent, Rockville, MD USA
[3] Agcy Healthcare Res & Qual, Rockville, MD USA
[4] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[5] Commun Med Alliance, Boston, MA USA
[6] Natl Inst Hlth, Off AIDS Res, Bethesda, MD USA
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2007年 / 19卷 / 09期
关键词
D O I
10.1080/09540120701351888
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
High levels of adherence to highly active antiretroviral therapy (HAART) are essential for virologic suppression and longer survival in patients with HIV. We examined the effects of substance abuse treatment, current versus former substance use, and hazardous/binge drinking on adherence to HAART. During 2003, 659 HIV patients on HAART in primary care were interviewed. Adherence was defined as >= 95% adherence to all antiretroviral medications. Current substance users used illicit drugs and/or hazardous/binge drinking within the past six months, while former users had not used substances for at least six months. Logistic regression analyses of adherence to HAART included demographic, clinical and substance abuse variables. Sixty-seven percent of the sample reported 95% adherence or greater. However, current users (60%) were significantly less likely to be adherent than former (68%) or never users (77%). In multivariate analysis, former users in substance abuse treatment were as adherent to HAART as never users (Adjusted Odds Ratio (AOR) = 0.82; p > 0.5). In contrast, former users who had not received recent substance abuse treatment were significantly less adherent than never users (AOR = 0.61; p = 0.05). Current substance users were significantly less adherent than never users, regardless of substance abuse treatment (p < 0.01). Substance abuse treatment interacts with current versus former drug use status to affect adherence to HAART. Substance abuse treatment may improve HAART adherence for former substance users.
引用
收藏
页码:1134 / 1140
页数:7
相关论文
共 23 条
[1]   Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users [J].
Arnsten, JH ;
Demas, PA ;
Grant, RW ;
Gourevitch, MN ;
Farzodegan, H ;
Howard, AA ;
Schoenboum, EE .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (05) :377-381
[2]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[3]   Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments [J].
Chesney, MA ;
Ickovics, JR ;
Chambers, DB ;
Gifford, AL ;
Neidig, J ;
Zwickl, B ;
Wu, AW .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (03) :255-266
[4]   Problem drinking and medication adherence among persons with HIV infection [J].
Cook, RL ;
Sereika, SM ;
Hunt, SC ;
Woodward, WC ;
Erlen, JA ;
Conigliaro, J .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2001, 16 (02) :83-88
[5]   The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV cost and services utilization study [J].
Galvan, FH ;
Bing, EG ;
Fleishman, JA ;
London, AS ;
Caetano, R ;
Burnam, MA ;
Longshore, D ;
Morton, SC ;
Orlando, M ;
Shapiro, M .
JOURNAL OF STUDIES ON ALCOHOL, 2002, 63 (02) :179-186
[6]  
Gebo KA, 2005, MED CARE, V43, P23
[7]   Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001 [J].
Gebo, KA ;
Fleishman, JA ;
Conviser, R ;
Reilly, ED ;
Korthuis, PT ;
Moore, RD ;
Hellinger, J ;
Keiser, P ;
Rubin, HR ;
Crane, L ;
Hellinger, FJ ;
Mathews, WC .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (01) :96-103
[8]  
Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386
[9]  
Ickovics JR, 2002, ANTIVIR THER, V7, P185
[10]  
JOSEPHS JS, IN PRESS HIV MED